Funder
Taiho Pharmaceutical, Tokyo, Japan
Subject
Gastroenterology,Oncology
Reference27 articles.
1. Colorectal cancer treatment: what's next? (or, Is there life after EGFR and VEGF?);Saltz;Gastrointest Cancer Res,2008
2. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen;Van Cutsem;J Clin Oncol,2012
3. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
4. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up;Van Cutsem;Ann Oncol,2009
5. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study;Douillard;J Clin Oncol,2010
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献